 Orgenesis NASDAQ:ORGS Inc announced second-quarter 2022 revenue of 7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a 10 million loan from investment firm Metalmark Capital Partners for Orgenesis NASDAQ:ORGS point of care POCare services business for treating patients. 